|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,166.50 JPY | +0.25% |
|
+0.86% | +3.51% |
| 07-12 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,881B 23.68B 20.84B 19.36B 17.78B 33.37B 2,287B 33.93B 228B 90.01B 1,121B 88.95B 87.03B | P/E 2027 * |
11.3x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,751B 22.88B 20.14B 18.71B 17.18B 32.25B 2,210B 32.8B 221B 86.99B 1,084B 85.97B 84.12B | EV / Sales 2027 * |
1.66x | EV / Sales 2028 * | 1.64x |
| Free-Float |
97.66% | Yield 2027 * |
3.71% | Yield 2028 * | 3.83% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.25% | ||
| 1 week | +0.86% | ||
| Current month | -0.39% | ||
| 1 month | +1.57% | ||
| 3 months | -12.52% | ||
| 6 months | -4.22% | ||
| Current year | +3.51% |
| 1 week | 2,131.5 |  | 2,218 |
| 1 month | 2,105 | | 2,218 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,474.5 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 2023-02-09 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 2023-10-31 |
Tatjana Dragovic
CMP | Compliance Officer | - | 2025-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 2023-02-09 |
Naoki Okamura
BRD | Director/Board Member | 63 | 2019-05-31 |
| Director/Board Member | 58 | 2023-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +0.86% | +45.65% | +4.28% | 23.62B | |
| +0.86% | +2.30% | +49.71% | +158.86% | 1,057B | |
| +1.59% | +5.37% | +55.77% | +54.77% | 624B | |
| +0.95% | +1.95% | +36.11% | +80.44% | 454B | |
| +1.60% | +7.09% | +35.90% | +29.32% | 341B | |
| -0.60% | +2.95% | +36.28% | +39.04% | 297B | |
| -0.14% | +0.33% | +18.70% | +17.64% | 262B | |
| +0.09% | -4.53% | -27.60% | -42.19% | 215B | |
| +1.22% | +1.20% | +21.61% | +60.14% | 201B | |
| -1.18% | -5.13% | +13.87% | +60.35% | 162B | |
| Average | +0.19% | +0.76% | +28.60% | +46.26% | 363.76B | |
| Weighted average by Cap. | +0.04% | +1.56% | +36.67% | +76.36% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,261B 13.79B 12.14B 11.28B 10.36B 19.44B 1,332B 19.77B 133B 52.43B 653B 51.82B 50.7B | 2,075B 12.66B 11.14B 10.35B 9.5B 17.84B 1,222B 18.14B 122B 48.11B 599B 47.55B 46.53B |
| Net income | 344B 2.1B 1.85B 1.72B 1.58B 2.96B 203B 3.01B 20.23B 7.98B 99.36B 7.88B 7.71B | 327B 2B 1.76B 1.63B 1.5B 2.82B 193B 2.86B 19.26B 7.59B 94.61B 7.51B 7.34B |
| Net Debt | -130B -793M -698M -649M -596M -1.12B -76.63B -1.14B -7.65B -3.02B -37.58B -2.98B -2.92B | -472B -2.88B -2.54B -2.36B -2.16B -4.06B -278B -4.13B -27.78B -10.95B -136B -10.82B -10.59B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-24 | JP¥2,166.50 | +0.25% | 4,657,000 |
| 26-07-23 | JP¥2,161.00 | -0.67% | 4,744,700 |
| 26-07-22 | JP¥2,175.50 | -0.96% | 7,982,000 |
| 26-07-21 | JP¥2,196.50 | +2.12% | 9,078,900 |
| 26-07-17 | JP¥2,151.00 | +0.14% | 10,798,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
